Every day, thousands of Americans seek treatment for opioid use disorder online at Bicycle Health. Our index provides quarterly insights on patients seeking treatment online.See OUD Index
Yes, A 2019 study in the Journal of Substance Abuse Treatment found that, at six months, only 3.6% of individuals who were adherent to MOUD with buprenorphine experienced a nonfatal drug-related overdose in the ED, compared to 13.2% of individuals who were non-adherent.
Yes, Telehealth reduces any barrier to access to addiction specialists
Yes, A 2013 study in JSAT found that patients who were adherent to MOUD treatment saw their total healthcare costs decrease by 42 percent ($28,458 vs. $49,051) when compared to non-adherent members.
Yes. A March, 2023 study in JAMA Psychiatry found an association between emergency authorized telehealth expansion and MOUD provision during the COVID-19 pandemic were associated with lower odds of fatal drug overdose among Medicare beneficiaries.
Yes. An August, 2022 study in JAMA Psychiatry showed the telehealth provision of MOUD from COVID-19 to be associated with improved retention in care and reduced odds of medically treated overdose for Medicare beneficiaries.
Yes. A July, 2022 study in the American Journal of Psychiatry found that Buprenorphine treatment for veterans with opioid use disorder increased as care shifted to telehealth during Covid.
Yes. A 2021 study in BMJ Innovations found the retention rate for insured telehealth patients at 90 days was 80% compared to an industry average of 44% and that “no-show rate” for telehealth patients was 9.5%, compared with an average of 23%.
Yes.A January, 2023 study in JAMA Open Network found that the percentage of opioid-related deaths involving buprenorphine dropped from 3.6% to 2.1% from July 2019 to June 2021, after the Ryan Haight Act was waived and telemedicine OUD care with no in-person requirement began. The same study from JAMA Open Network found that buprenorphine-involved deaths were more likely to involve other drugs (at least one), and less likely to involve illicitly manufactured fentanyl compared to other opioid-involved overdose deaths (50.2% vs. 85.3%).
To treat withdrawal. A 2021 study covered in JAMA Network Open, found that hydrocodone and oxycodone were far more commonly misused than buprenorphine and that when buprenorphine is misused, the reason tends to be self-medication of withdrawal symptoms and pain, not to get high. The primary reported motivation for use of diverted buprenorphine to be lack of access to legitimate treatment for OUD. The rate of use of diverted buprenorphine was highest by far in the population of patients with OUD not receiving MOUD.
Yes. Over 97% of patients receiving MOUD treatment via telehealth complete their Urine Drug Screenings (JAMA Health Forum)